keyword
MENU ▼
Read by QxMD icon Read
search

bone metastases

keyword
https://www.readbyqxmd.com/read/28213624/oligometastatic-colorectal-cancer-is-single-site-bony-colorectal-metastasis-a-treatable-condition
#1
Noel Cassar, Adrian Ben Cresswell, Brendan Moran
INTRODUCTION: A potentially resectable bony metastasis in the context of oligometastatic colorectal cancer is uncommon. Bony metastases are usually considered a late event with poor prognosis and generally associated with liver and/or lung metastases. INDEX CASE: A previously healthy 33-year-old gentleman, with no family history of colorectal cancer, presented with rectal bleeding and at colonoscopy had a biopsy-proven adenocarcinoma of the rectum, 7 cm from the anal verge...
February 17, 2017: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/28211502/bisphosphonates-enhance-antitumor-effect-of-egfr-tkis-in-patients-with-advanced-egfr-mutant-nsclc-and-bone-metastases
#2
Guowei Zhang, Ruirui Cheng, Zengli Zhang, Tao Jiang, Shengxiang Ren, Zhiyong Ma, Sha Zhao, Caicun Zhou, Jun Zhang
Whether bisphosphonates could enhance the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation and bone metastases (BM) remains unknown. EGFR mutation status were collected from 1560 patients with NSCLC and BM. 356 NSCLC patients with EGFR mutation and BM were identified. Among them, 91 patients received EGFR-TKIs alone and 105 patients received EGFR-TKIs plus bisphosphonates as first-line therapy. Comparing to TKIs alone, EGFR-TKIs plus bisphosphonates had a statistically significant longer progression-free survival (PFS: 11...
February 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28211081/h3f3a-mutation-in-giant-cell-tumour-of-the-bone-is-detected-by-immunohistochemistry-using-a-monoclonal-antibody-against-the-g34w-mutated-site-of-the-histone-h3-3-variant
#3
Julian Lüke, Alexandra von Baer, Jordan Schreiber, Christoph Lübbehüsen, Thomas Breining, Kevin Mellert, Ralf Marienfeld, Markus Schultheiss, Peter Möller, Thomas Fe Barth
AIMS: Giant cell tumour of bone (GCTB) is a neoplasm predominantly of long bones characterised by the H3F3A mutation G34W. Conventional diagnostic is challenged by the tumour's giant cell-rich morphology, which overlaps with other giant cell containing lesions of the bone. Recently, a monoclonal antibody specific for the H3F3A mutation has been generated. Our aim was to test this antibody on a cohort of giant cell containing lesions. METHODS AND RESULTS: We used the antibody for analysis of 22 H3F3A-mutated GCTB, including two patients with recurrences; for comparison we analysed a cohort of 36 H3F3A-wild-type giant cell-rich lesions of the bone and soft tissue, containing one brown tumour, six aneurysmal bone cysts, six chondroblastomas, five non-ossifying-fibromas, two fibrous dysplasias, nine tenosynovial giant cell tumours, one giant cell-rich sarcoma and six osteosarcomas...
February 17, 2017: Histopathology
https://www.readbyqxmd.com/read/28210997/3d-skeletal-uptake-of-18-f-sodium-fluoride-in-pet-ct-images-is-associated-with-overall-survival-in-patients-with-prostate-cancer
#4
Sarah Lindgren Belal, May Sadik, Reza Kaboteh, Nezar Hasani, Olof Enqvist, Linus Svärm, Fredrik Kahl, Jane Simonsen, Mads H Poulsen, Mattias Ohlsson, Poul F Høilund-Carlsen, Lars Edenbrandt, Elin Trägårdh
BACKGROUND: Sodium fluoride (NaF) positron emission tomography combined with computer tomography (PET/CT) has shown to be more sensitive than the whole-body bone scan in the detection of skeletal uptake due to metastases in prostate cancer. We aimed to calculate a 3D index for NaF PET/CT and investigate its correlation to the bone scan index (BSI) and overall survival (OS) in a group of patients with prostate cancer. METHODS: NaF PET/CT and bone scans were studied in 48 patients with prostate cancer...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28209069/patterns-of-care-and-survival-outcomes-of-palliative-radiation-for-prostate-cancer-with-bone-metastases-comparison-of-%C3%A2-5-fractions-to-%C3%A2-10-fractions
#5
David Schreiber, Joseph Safdieh, Daniel J Becker, David Schwartz
BACKGROUND: To review the palliative radiation fractionation regimens, trends and survival of men within the National Cancer Database (NCDB) diagnosed with prostate cancer and bony metastases. METHODS: A total of 3,871 patients from the NCDB were included in the analysis (patients treated from 2004-2012). The following fractionation regimens were analyzed [8 Gy × 1, 4 Gy × 5 (short course radiation therapy)], were compared to 3 Gy × 10, 2.50 Gy × 14-15 and 2 Gy × 20-30 (long course radiation therapy)...
January 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/28209068/urinary-cytokines-chemokines-after-magnetic-resonance-guided-high-intensity-focused-ultrasound-for-palliative-treatment-of-painful-bone-metastases
#6
Ahmad Bushehri, Gregory Czarnota, Liying Zhang, Kullervo Hynynen, Yuexi Huang, Michael Chan, William Chu, Kristopher Dennis, Charles Mougenot, Jennifer Coccagna, Arjun Sahgal, Edward Chow, Carlo DeAngelis
BACKGROUND: Pain is experienced by 50-75% of patients with bone metastases, representing a major source of morbidity amongst cancer patients. Magnetic resonance-guided high intensity focused ultrasound (MRgHIFU) is a new, non-invasive, outpatient treatment modality for painful bone metastases. The aim of this study was to analyze urinary cytokines/chemokines pattern after MRgHIFU for palliative treatment of painful bone metastases. The findings were compared to the cytokines/chemokines pattern post single 8 Gy fraction radiation from our previous study...
January 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/28208989/central-telangiectatic-osteosarcoma-of-the-mandible-in-a-paediatric-patient-a-rarity
#7
Divya Tomar, Manu Dhillon, Muhamad Nishad Thayath, Iram Zaidi, Shikha Singh
Osteosarcoma (OS) involving the head and neck region is rare and is a diagnostic challenge due to its aggressive nature and varied presentations. Although OS constitute 40% to 60% of all bone tumours, only 10% of these occur in the head and neck region, most commonly in the maxilla and mandible. OS of the jaw bone has a different pattern and behaviour when compared to OS at other anatomic location. It occurs in a more elderly population, less aggressive and usually spreads locally rather than distant metastases...
December 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28207199/bisphosphonate-functionalized-imaging-agents-anti-tumor-agents-and-nanocarriers-for-treatment-of-bone-cancer
#8
REVIEW
Robin A Nadar, Nicola Margiotta, Michele Iafisco, Jeroen J J P van den Beucken, Otto C Boerman, Sander C G Leeuwenburgh
Bone metastases result from the invasion of primary tumors to bone. Current treatment modalities include local treatments such as surgery and radiotherapy, while systemic treatments include chemotherapy and (palliative) treatment of skeletal metastases. Nevertheless, once bone metastases have been established they remain incurable leading to morbidity and mortality. Bisphosphonates are a well-established class of drugs, which are increasingly applied in the treatment of bone cancers owing to their effective inhibition of tumor cells and suppression of bone metastases...
February 16, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28207159/the-critical-role-of-the-znf217-oncogene-in-promoting-breast-cancer-metastasis-to-the-bone
#9
Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca-Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean-Luc Coll, Isabelle Treilleux, Véronique Maguer-Satta, Véronique Josserand, Pascale A Cohen
Bone metastasis affects more than 70% of patients with advanced breast cancer. However, the molecular mechanisms underlying this process remain unclear. Based on the analysis of clinical datasets, and in vitro and in vivo experiments, we report that the ZNF217 oncogene is a crucial mediator and indicator of bone metastasis. Patients with high ZNF217 mRNA expression levels in primary breast tumours had a higher risk of developing bone metastases. MDA-MB-231 breast cancer cells stably transfected with ZNF217 (MDA-MB-231-ZNF217) displayed the dysregulated expression of a set of genes with bone homing and metastasis characteristics, which overlapped with two previously described "osteolytic bone metastasis" gene signatures, while also highlighting the bone morphogenetic protein (BMP) pathway...
February 16, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28203179/malignant-phyllodes-tumor-presenting-in-bone-brain-lungs-and-lymph-nodes
#10
Eric D Johnson, Evin Gulbahce, Joseph McNally, Saundra S Buys
INTRODUCTION: Phyllodes tumors (PTs) are rare fibroepithelial tumors of the breast which are classified as benign, borderline, or malignant. Malignant PTs account for <1% of malignant breast tumors, and borderline tumors have potential to progress to malignant tumors. Metastatic recurrences are most commonly documented in bone and lungs. We report an extremely rare presentation of recurrent malignant PTs involving the brain, lung, lymph nodes, and bone. CASE: A 66-year-old female presented with a large breast mass...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/28203166/gastrointestinal-stromal-tumour-with-synchronous-bone-metastases-a-case-report-and-literature-review
#11
Philippe Rochigneux, Lénaig Mescam-Mancini, Delphine Perrot, Erwan Bories, Laurence Moureau-Zabotto, Anthony Sarran, Jérôme Guiramand, François Bertucci
Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours of the digestive tract, derived from Cajal interstitial cells. Bone metastases are very rare, and there is no consensus regarding their treatment. Here, we present the unusual case of a 66-year-old man with a gastric GIST with synchronous bone and liver metastases, fully documented at the pathological and molecular levels with a KIT exon 11 mutation. After 9 months of imatinib, the scanner showed a 33% partial response of target lesions. We also review the literature and describe the characteristics, treatment, and outcome of all cases previously reported...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28203089/impact-of-tumor-volume-doubling-time-on-post-metastatic-survival-in-bone-or-soft-tissue-sarcoma-patients-treated-with-metastasectomy-and-or-radiofrequency-ablation-of-the-lung
#12
Tomoki Nakamura, Akihiko Matsumine, Motoshi Takao, Atsuhiro Nakatsuka, Takao Matsubara, Kunihiro Asanuma, Akihiro Sudo
Metastasectomy represents the standard treatment for improving survival in patients with lung metastases (LMs) from bone (BS) or soft-tissue sarcoma (STS). Recently, radiofrequency ablation (RFA) of the LMs has been proved to be a useful option which can promise the similar effect to metastasectomy. The aim of this study was to determine prognostic factors, including tumor volume doubling time (TVDT), for post-metastatic survival in BS and STS patients treated with metastasectomy and/or RFA of the lung. Forty-eight patients with LMs were retrospectively reviewed...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28203088/peptide-receptor-radionuclide-therapy-in-the-management-of-gastrointestinal-neuroendocrine-tumors-efficacy-profile-safety-and-quality-of-life
#13
REVIEW
Stefano Severi, Ilaria Grassi, Silvia Nicolini, Maddalena Sansovini, Alberto Bongiovanni, Giovanni Paganelli
Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitting radioisotope. The compounds differ from each other in terms of their energetic features (due to the radionuclide) and peptide receptor affinity (due to the analog) but share the common characteristic of binding specific membrane somatostatin receptors that are (generally) overexpressed in neuroendocrine neoplasms (NENs) and their metastases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28203086/clinical-investigation-into-the-initial-diagnosis-and-treatment-of-539-patients-with-stage-iv-lung-cancer
#14
Qian Shao, Shanshan Liu, Wei Wang, Yingjie Zhang, Fengxiang Li, Jianbin Li
OBJECTIVE: The aim of the study was to analyze clinical data, including the types of pathologic classification, metastatic organs, treatment strategy, and prognosis of patients with stage IV lung cancer. METHODS: A retrospective analysis of the clinical features of 539 patients with stage IV lung cancer who were initially diagnosed and treated in 2009 was conducted. There were 146 cases of single organ metastases and 393 cases of multiple organ metastases. The Kaplan-Meier method and multivariate Cox regression analysis were performed to analyze the influence of age, pathological classification, metastatic organs, and treatment strategy on overall survival...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28202531/the-role-of-megakaryocytes-in-breast-cancer-metastasis-to-bone
#15
Walter Jackson, Donna M Sosnoski, Sara E Ohanessian, Paige Chandler, Adam W Mobley, Kacey D Meisel, Andrea M Mastro
Little is known about how megakaryocytes affect metastasis apart from serving as the source of platelets. We noted an increase in the number of megakaryocytes in the femurs of metastases-bearing athymic mice four weeks following intracardiac inoculation of MDA-MB-231 human breast cancer cells. How did the megakaryocytes relate to the metastases? Did megakaryocytes prepare a niche or did they increase in response to metastases? To test these possibilities, we examined two models of experimental metastasis, intracardiac inoculation of human MDA-MB-231 into athymic mice, and intramammary injection of mouse tumor cells, 4T1...
February 15, 2017: Cancer Research
https://www.readbyqxmd.com/read/28202520/evolution-of-cancer-stem-like-cells-in-endocrine-resistant-metastatic-breast-cancers-is-mediated-by-stromal-microvesicles
#16
Pasquale Sansone, Marjan Berishaj, Vinagolu K Rajasekhar, Claudio Ceccarelli, Qing Chang, Antonio Strillacci, Claudia Savini, Lauren Shapiro, Robert Bowman, Chiara Mastroleo, Sabrina De Carolis, Laura Daly, Alberto Benito-Martin, Fabiana Perna, Nicola Fabbri, John H Healey, Enzo Spisni, Monica Cricca, David Lyden, Massimiliano Bonafé, Jacqueline Bromberg
The hypothesis that microvesicle (MV)-mediated microRNA transfer converts non-cancer stem cells into cancer stem cells (CSCs) leading to therapy resistance remains poorly investigated. Here we provide direct evidence supporting this hypothesis, by demonstrating how MV derived from cancer associated fibroblasts (CAF) transfer miR-221 to promote hormonal therapy resistance (HTR) in models of luminal breast cancer. We determined that CAF-derived MV horizontally transferred miR221 to tumor cells and, in combination with hormone therapy activated an ERlo/Notchhi feed-forward loop responsible for the generation of CD133hi CSC...
February 15, 2017: Cancer Research
https://www.readbyqxmd.com/read/28201973/flavonoids-active-against-osteosarcoma-a-review-of-the-molecular-mechanisms-involved
#17
Hui Liu, Yutong Gao, Yonghui Dong, Peng Cheng, Anmin Chen, Hui Huang
Osteosarcoma is the most frequent primitive malignant bone tumor affecting adolescents and young adults worldwide. The tumor exhibits aggressive growth in the primary site and readily metastasizes to other organs. There has been no significant improvement in the 5-year survival rate since the 1970s and the figure remains at 60-70%. In addition, the side effects of chemotherapeutic drugs and resistance to chemotherapy compromise the effects of treatment for osteosarcoma. In recent years, the development of flavonoids drugs inhibiting carcinogenesis is attracting great interest in the scientific community...
February 14, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28199984/autocrine-and-paracrine-stip1-signaling-promote-osteolytic-bone-metastasis-in-renal-cell-carcinoma
#18
Jiang Wang, Hongbo You, Jun Qi, Caihong Yang, Ye Ren, Hao Cheng
Bone metastases are responsible for some of the most devastating complications of renal cell carcinoma (RCC). However, pro-metastatic factors leading to the highly osteolytic characteristics of RCC bone metastasis have barely been explored. We previously developed novel bone-seeking RCC cell lines by the in vivo selection strategy and performed a comparative proteome analysis on their total cell lysate. Here, we focused on STIP1 (stress-induced phosphoprotein 1), the high up-regulated protein in the bone-seeking cells, and explored its clinical relevance and functions in RCC bone metastasis...
February 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28197305/ca-2-selective-host-rotaxane-is-highly-toxic-against-prostate-cancer-cells
#19
David B Smithrud, Lucas Powers, Jennifer Lunn, Scott Abernathy, Michael Peschka, Shuk-Mei Ho, Pheruza Tarapore
New therapies are needed to eradicate androgen resistant, prostate cancer. Prostate cancer usually metastasizes to bone where the concentration of calcium is high, making Ca(2+) a promising toxin. Ionophores can deliver metal cations into cells, but are currently too toxic for human use. We synthesized a new rotaxane (CEHR2) that contains a benzyl 15-crown-5 ether as a blocking group to efficiently bind Ca(2+). CEHR2 transfers Ca(2+) from an aqueous solution into CHCl3 to greater extent than alkali metal cations and Mg(2+)...
February 9, 2017: ACS Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28196208/effect-of-radiotherapy-on-painful-bone-metastases-a-secondary-analysis-of-the-ncic-clinical-trials-group-symptom-control-trial-sc-23
#20
Rachel McDonald, Keyue Ding, Michael Brundage, Ralph M Meyer, Abdenour Nabid, Pierre Chabot, Genevieve Coulombe, Shahida Ahmed, Joda Kuk, A Rashid Dar, Aamer Mahmud, Alysa Fairchild, Carolyn F Wilson, Jackson S Y Wu, Kristopher Dennis, Carlo DeAngelis, Rebecca K S Wong, Liting Zhu, Stephanie Chan, Edward Chow
Importance: Many studies that found improved quality of life (QOL) after radiotherapy of bone metastases have small sample sizes and do not use specific questionnaires. How soon after radiotherapy one can expect an improvement in QOL is unknown. Objective: To investigate QOL at days 10 and 42 after radiotherapy with a bone metastases-specific QOL tool. Design, Setting, and Participants: In this secondary analysis of the NCIC Clinical Trials Group Symptom Control Trial SC...
February 9, 2017: JAMA Oncology
keyword
keyword
61123
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"